Associated Papers
An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub-Saharan African Ancestry.
Oni-Orisan A et al.
Clinical Pharmacology and Therapeutics, 2025
Retrospective Evaluation of the Impact of SLCO1B1 Variation on Statin Effectiveness.
Ahmed Feldman M et al.
Journal of Personalized Medicine, 2025
SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.
Haldar T et al.
Clinical Pharmacology and Therapeutics, 2025
SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report.
Medwid S et al.
British Journal of Clinical Pharmacology, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia.
Chen C et al.
Pharmacogenomics and Personalized Medicine, 2024
SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study.
Yee SW et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
Weiner M et al.
Antimicrobial Agents and Chemotherapy, 2018
Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen.
Gao CM et al.
Oncology Reports, 2017
Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).
Lee HH et al.
British Journal of Clinical Pharmacology, 2017
Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.
Mladenovska K et al.
Die Pharmazie, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Mapping SLCO1B1 Genetic Variation for Global Precision Medicine in Understudied Regions in Africa: A Focus on Zulu and Cape Admixed Populations.
Hoosain N et al.
Omics : a Journal of Integrative Biology, 2016
Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S et al.
Environmental Toxicology and Pharmacology, 2015
Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A et al.
Die Pharmazie, 2015
Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.
Grapci AD et al.
Balkan Journal of Medical Genetics : Bjmg, 2015
Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.
Lee E et al.
Breast Cancer Research : Bcr, 2014
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
Baietto L et al.
Current Drug Metabolism, 2014
Influence of the functional polymorphisms in the organic anion transporting polypeptide 1B1 in the susceptibility to colorectal cancer.
Ozhan G et al.
Genetic Testing and Molecular Biomarkers, 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB et al.
Genome Research, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M et al.
Pharmacological Reviews, 2011
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Weiner M et al.
Antimicrobial Agents and Chemotherapy, 2010
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
Oswald S et al.
Pharmacogenetics and Genomics, 2008
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.
Mwinyi J et al.
European Journal of Clinical Pharmacology, 2008
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
Seithel A et al.
Molecular Genetics and Genomics : Mgg, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients.
Xu LY et al.
Acta Pharmacologica Sinica, 2007
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007
Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1.
Hänggi E et al.
Molecular Pharmacology, 2006
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA et al.
Clinical Pharmacology and Therapeutics, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).
Iwai M et al.
Pharmacogenetics, 2004
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Nishizato Y et al.
Clinical Pharmacology and Therapeutics, 2003
An evolutionarily ancient Oatp: insights into conserved functional domains of these proteins.
Cai SY et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology, 2002
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
Tirona RG et al.
The Journal of Biological Chemistry, 2001